A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.

By George A. Calin, M. Ferracin, A. Cimmino, Gianpiero di Leva, M. Shimizu, Sylwia E. Wojcik, Marilena V. Iorio, R. Visone, Nurettin Ilfer Sever, M. Fabbri and 13 more. New England Journal of Medicine, 2005

2,531 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Immunology

View Paper: https://www.semanticscholar.org/paper/635b67e82407bc927c98fcabceea680c37fc0ac5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Genetics

In Immunology

Citations in the corpus

Detection of microRNA Expression in Human Peripheral Blood Microvesicles (2008, background): “Later, several studies showed the importance of miRNA in prognosis, initiation and progression of numerous cancer types [16–18].”
MicroRNAs and cancer: short RNAs go a long way. (2009, background): “…cancers, elevated expression of miR-21 is associated with poor survival (Schetter et al., 2008), whereas in chronic lymphocytic leukemias an miRNA “signature” composed of 13 miRNAs is associ- 590 Cell 136, February 20, 2009 ©2009 Elsevier Inc. ated with disease progression (Calin et al., 2005).”
microRNAs as oncogenes and tumor suppressors. (2007, background): “In addition, miRNA microarray technology has been widely used to study the roles of miRNA in cancers (Calin et al., 2005; Iorio et al., 2005; Lu et al., 2005), with several miRNA oncogenes and tumor suppressor genes identified.”
MicroRNAs in cell proliferation, cell death, and tumorigenesis (2006, background): “Thus, loss of these miRNAs may contribute to elevated Bcl2 expression and pathologic cell survival in B-CLL. miRNAs IN CELL CYCLE PROGRESSION AND STEM CELL MAINTENANCE Both cancer cells and stem cells share an ability to divide continuously without undergoing senescence.”
MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. (2007, background): “Dysregulated miRNA expression may occur via a number of mechanisms, such as gene copy gain or loss (4), germline mutation of precursor miRNA molecules (5), promoter methylation (6), or aberrant miRNA processing due to altered expression of miRNA biogenesis machinery (7).”
Genetic variants of miRNA sequences and non-small cell lung cancer survival. (2008, neutral): “Inherited mutations or rare SNPs in the primary transcripts of has-mir-15a and has-mir-16-1 have been linked to familial chronic lymphocytic leukemia and familial breast cancer (15), which was further supported in a spontaneous mouse model of chronic lymphocytic leukemia (16).”
MicroRNAs in cancer: small molecules with a huge impact. (2009, background): “In two cases, the mutant was in homozygosity in the leukemic cells, whereas normal cells of the two patients were heterozygous for this abnormality, indicating a loss of the normal miR-15/16 allele in the leukemic cell.(6) Thus miR-15a and miR-16-1 behave like typical tumor suppressors in CLL.”
MicroRNAs in human cancer. (2013, background): “So far the only mutation identi fi ed in a miRNA that could lead to malignancy is miR16, where a germline mutation potentially affects miR-16 biogenesis and abundance in a kindred with familial CLL [ 188 ] and New Zealand black mice that naturally develop CLL-like disease [ 189 ] .”
Non-coding RNA. (2006, methodology): “miRNA expression is dysregulated in cancer cells (143,149,150) and miRNA profiling can be used as a very accurate diagnostic tool for cancer classification (151,152).”
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. (2007, background): “Recent description of a micro-RNA–based mechanism by which CLL cells express high levels of BCL2 (32) combined with development of a small molecule antagonist of BCL2 (15) make timely a mechanistic investigation into the role of BCL2 in CLL cell maintenance.”
Genetic variation in microRNA networks: the implications for cancer research (2010, neutral): “The first evidence that point mutations in miRNA genes can have a functional effect and confer cancer susceptibility comes from a seminal study by Carlo Croce's grou”